Last reviewed · How we verify
Convalescent Plasma
Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.
Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease. Used for COVID-19 (severe or life-threatening disease), Emerging infectious diseases (investigational).
At a glance
| Generic name | Convalescent Plasma |
|---|---|
| Also known as | Plasma therapy, Plasma, Not appicable, no apply, Fresh Frozen Plasma (FFP) |
| Sponsor | Hackensack Meridian Health |
| Drug class | Immunoglobulin/Passive immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Convalescent plasma is collected from individuals who have recovered from a specific infection and contains pathogen-specific antibodies and other immune components. When transfused into acutely ill patients, these antibodies provide immediate passive immunity to help neutralize the pathogen and modulate the immune response. This approach leverages the donor's adaptive immune response to support the recipient's own immune system during acute infection.
Approved indications
- COVID-19 (severe or life-threatening disease)
- Emerging infectious diseases (investigational)
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Circulatory overload
- Transfusion-transmitted infection
Key clinical trials
- Study Testing Convalescent Plasma vs Best Supportive Care (PHASE1)
- Intermediate IND Severe Illness COVID-19 CP (PHASE1)
- Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
- Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)
- Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases
- Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study (PHASE3)
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients (PHASE2)
- Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Convalescent Plasma CI brief — competitive landscape report
- Convalescent Plasma updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI